Rx-To-OTC Switch Of Low-Cost Smoking Cessation Drug Cystine Rejected By German Committee
Executive Summary
Low-cost smoking cessation alternaitve cystine and azelastine-fluticasone combination nasal spray Rx-to-OTC switch applications were rejected by Germany's independent Expert Committee on Prescription at its latest meeting. Olopatadine for ophthalmic use and oral bilastine at 10mg strength were, however, given the green light.
You may also be interested in...
Why Did Germany Reject OTC Switch Of Low-Cost Smoking Cessation Drug Cytisine?
At its first meeting of 2023, Germany's switch committee voted against switching to OTC status low-cost smoking cessation drug cytisine. Complex treatment guidelines and concerns about side effects were among the considerations leading to this decision, the recently published minutes show.
German OTC Market News: Allergy, Pain And Sleep Launches From Sanofi, Teva And P&G
The latest German consumer healthcare launches: Sanofi adds bilastine antihistamine to Allegra range; Teva's Ratiopharm delivers paracetamol and ibuprofen combo thanks to Rx-to-OTC switch; and P&G livens up WICK ZzzQuil sleep aid gummies with tropical fruit flavour.
Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda
Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.